IMMU Mendus AB (publ)
6.150SEK-0.81%Mkt Cap: 37.34M $P/E: —1d ago
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for t…
Industry Peers
Biotechnology$127.54BUSDP/E 29.3
$81.13BUSD
$74.79BUSDP/E 18.0
$57.11BUSDP/E 34.8
$55.24BUSDP/E 36.1
$44.51BUSD
$41.63BUSDP/E 17.7
$41.14BUSDP/E 64.7
$32.74BUSDP/E 30.1
$29.42BUSDP/E 37.1
$25.84BUSD
$24.53BUSD
$24.01BUSDP/E 30.3
$23.13BUSDP/E 14.5
$22.67BUSD
$21.61BUSDP/E 29.3
$15.32BUSDP/E 16.2
$15.01BUSDP/E 17.5
$14.58BUSDP/E 18.6
$13.78BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Mendus AB (FRA:1YG0) (Q2 2026) Earnings Call Highlights: ADVANCE-II Validation and Strategic ... Mendus AB (FRA:1YG0) reports reduced costs and extended cash runway while advancing key trials in AML and CML, positioning for significant clinical milestones through 2027. | ||
VVia TT | ||